Sino Biopharmaceutical Limited (HKG:1177)

Sino Biopharmaceutical Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	161,141	58,258	63,845	84,459	102,408	140,925
Market Cap Growth	69.78%	-8.75%	-24.41%	-17.53%	-27.33%	3.10%
Enterprise Value	166,112	64,462	66,382	90,167	114,126	146,103
Last Close Price	9.01	3.16	3.35	4.32	5.03	6.85
PE Ratio	38.19	15.64	24.85	29.37	5.71	42.82
Forward PE	33.61	17.48	17.77	20.63	12.33	33.15
PS Ratio	4.81	1.90	2.21	2.87	3.11	5.02
PB Ratio	3.21	1.28	1.52	1.97	2.21	5.29
P/TBV Ratio	4.86	1.78	1.96	2.59	2.84	7.22
P/FCF Ratio	-	9.68	11.60	14.88	22.84	30.42
P/OCF Ratio	-	8.28	9.55	11.93	15.55	22.28
PEG Ratio	1.28	1.24	1.34	-	0.62	3.97
EV/Sales Ratio	4.96	2.10	2.30	3.07	3.46	5.20
EV/EBITDA Ratio	22.08	8.79	9.45	12.75	17.05	21.73
EV/EBIT Ratio	26.55	10.44	11.08	14.81	20.07	30.02
EV/FCF Ratio	-	10.71	12.06	15.88	25.46	31.54
Debt / Equity Ratio	0.26	0.23	0.33	0.37	0.33	0.63
Debt / EBITDA Ratio	1.73	1.39	1.97	2.22	2.21	2.48
Debt / FCF Ratio	-	1.72	2.54	2.81	3.36	3.64
Asset Turnover	0.43	0.45	0.41	0.42	0.50	0.56
Inventory Turnover	2.83	2.44	2.31	2.10	2.79	2.93
Quick Ratio	1.14	1.11	0.90	1.15	1.38	1.87
Current Ratio	1.36	1.26	1.05	1.29	1.53	2.08
Return on Equity (ROE)	15.40%	11.82%	12.12%	11.94%	55.25%	20.20%
Return on Assets (ROA)	5.07%	5.62%	5.33%	5.40%	5.37%	6.05%
Return on Capital (ROIC)	6.55%	7.02%	6.60%	6.60%	6.69%	7.79%
Return on Capital Employed (ROCE)	11.50%	12.70%	13.30%	12.30%	10.30%	11.30%
Earnings Yield	2.63%	6.39%	4.02%	3.40%	17.51%	2.33%
FCF Yield	-	10.33%	8.62%	6.72%	4.38%	3.29%
Dividend Yield	1.12%	2.20%	1.46%	2.78%	1.59%	1.07%
Payout Ratio	-	52.76%	27.13%	49.84%	6.42%	42.84%
Buyback Yield / Dilution	2.10%	1.26%	2.57%	1.38%	-2.57%	0.06%
Total Shareholder Return	3.22%	3.46%	4.03%	4.16%	-0.98%	1.13%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.